2021
Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Smetana GW, Tetrault JM, Hill KP, Burns RB. Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Annals Of Internal Medicine 2021, 174: 237-246. PMID: 33556279, DOI: 10.7326/m20-7945.Peer-Reviewed Original ResearchConceptsNeuropathic painChronic painBeth Israel Deaconess Medical CenterPlacebo-treated patientsChronic neuropathic painPainful diabetic neuropathyPotential therapeutic effectsPrimary care practicesEvidence Review GroupEffects of cannabisNoncancer painPainful neuropathyDiabetic neuropathyTherapeutic effectMedical CenterGeneral internistsPainMedical cannabisReview GroupPatientsCare practicesSystematic reviewAddiction medicineCBD productsPatient interest
2019
The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortex